Febrile neutropenia rates with adjuvant docetaxel and cyclophophamide chemotherapy in early breast cancer: discrepancy between published reports and community
BRAJDC Protocol
24 juin 2021 completion of local treatment and neoadjuvant or adjuvant chemotherapy was as- sociated with significantly longer survival free of invasive ...
Brandt and colleagues performed a timely retrospective study and compared 330 cT2-4N0-1M0 NSCLC patients who received neoadjuvant chemotherapy or adjuvant.
between neoadjuvant and adjuvant chemotherapy (5). This trial recruited 624 patients with stage I–IIIA N0–N1. NSCLC and randomized them to three treatment
PB R
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of
BRAJACTW Protocol
1 juin 2017 vant taxane and anthracycline chemotherapy have a 20 to 30% risk of relapse.2 Patients with HER2- negative cancer who receive neoadjuvant ...
6 mai 2021 The addition of a third chemotherapy agent to standard paclitaxel and carboplatin is not recommended for use as adjuvant therapy in women ...
4 juin 2021 adjuvant and neoadjuvant chemotherapy in early breast cancer. Kenji Tezuka1*. Kotaro Miura2
s
Objective: Comparative survival between neoadjuvant chemotherapy and adju- vant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer.
11 janv. 2007 Adjuvant and Neoadjuvant Chemotherapy for Ewing Sarcoma Family Tumors in Patients Aged Between 40 and 60. Report of 35 Cases and Comparison ...